Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...

Pfizer (PFE) and Pioneering Medicines, Flagship Pioneering’s in-house drug discovery and development unit, announced an agreement to discover ...

“Autoimmune diseases impose a substantial ... sixth collaboration for the $7 billion biobucks, 10-program collaboration between Pfizer and Flagship that was first announced in 2023.

FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Collaboration leverages ... and development unit, and Pfizer, to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases.

Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical app ...

"Sanofi's dedication to this program expands our mutual drug discovery pipeline in autoimmune disease and ... multiple additional programs under collaboration agreements with Gilead Sciences, Inc., ...